Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Gut microbiome and prostate cancer.
Fujita K, Matsushita M, Banno E, De Velasco MA, Hatano K, Nonomura N, Uemura H. Fujita K, et al. Among authors: banno e. Int J Urol. 2022 Aug;29(8):793-798. doi: 10.1111/iju.14894. Epub 2022 Apr 6. Int J Urol. 2022. PMID: 35388531 Review.
MEK inhibitor for gastric cancer with MEK1 gene mutations.
Sogabe S, Togashi Y, Kato H, Kogita A, Mizukami T, Sakamoto Y, Banno E, Terashima M, Hayashi H, de Velasco MA, Sakai K, Fujita Y, Tomida S, Yasuda T, Takeyama Y, Okuno K, Nishio K. Sogabe S, et al. Among authors: banno e. Mol Cancer Ther. 2014 Dec;13(12):3098-106. doi: 10.1158/1535-7163.MCT-14-0429. Epub 2014 Sep 24. Mol Cancer Ther. 2014. PMID: 25253779
An activating ALK gene mutation in ALK IHC-positive/FISH-negative nonsmall-cell lung cancer.
Togashi Y, Mizuuchi H, Kobayashi Y, Hayashi H, Terashima M, Sakai K, Banno E, Mizukami T, Nakamura Y, de Velasco MA, Fujita Y, Tomida S, Mitsudomi T, Nishio K. Togashi Y, et al. Among authors: banno e. Ann Oncol. 2015 Aug;26(8):1800-1. doi: 10.1093/annonc/mdv240. Epub 2015 May 22. Ann Oncol. 2015. PMID: 26002608 Free article. No abstract available.
Functional Analyses of Mutations in Receptor Tyrosine Kinase Genes in Non-Small Cell Lung Cancer: Double-Edged Sword of DDR2.
Terashima M, Togashi Y, Sato K, Mizuuchi H, Sakai K, Suda K, Nakamura Y, Banno E, Hayashi H, De Velasco MA, Fujita Y, Tomida S, Mitsudomi T, Nishio K. Terashima M, et al. Among authors: banno e. Clin Cancer Res. 2016 Jul 15;22(14):3663-71. doi: 10.1158/1078-0432.CCR-15-2093. Epub 2016 Jan 29. Clin Cancer Res. 2016. PMID: 26826182
Significance of FGF9 gene in resistance to anti-EGFR therapies targeting colorectal cancer: A subset of colorectal cancer patients with FGF9 upregulation may be resistant to anti-EGFR therapies.
Mizukami T, Togashi Y, Naruki S, Banno E, Terashima M, de Velasco MA, Sakai K, Yoneshige A, Hayashi H, Fujita Y, Tomida S, Nakajima TE, Fujino T, Boku N, Ito A, Nakagawa K, Nishio K. Mizukami T, et al. Among authors: banno e. Mol Carcinog. 2017 Jan;56(1):106-117. doi: 10.1002/mc.22476. Epub 2016 Feb 24. Mol Carcinog. 2017. PMID: 26916220
Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC.
Nakamura Y, Togashi Y, Nakahara H, Tomida S, Banno E, Terashima M, Hayashi H, de Velasco MA, Sakai K, Fujita Y, Okegawa T, Nutahara K, Hamada S, Nishio K. Nakamura Y, et al. Among authors: banno e. Mol Cancer Ther. 2016 Aug;15(8):1988-97. doi: 10.1158/1535-7163.MCT-15-0737. Epub 2016 May 20. Mol Cancer Ther. 2016. PMID: 27207775
Sensitivities to various epidermal growth factor receptor-tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor-tyrosine kinase inhibitor?
Banno E, Togashi Y, Nakamura Y, Chiba M, Kobayashi Y, Hayashi H, Terashima M, de Velasco MA, Sakai K, Fujita Y, Mitsudomi T, Nishio K. Banno E, et al. Cancer Sci. 2016 Aug;107(8):1134-40. doi: 10.1111/cas.12980. Epub 2016 Jul 14. Cancer Sci. 2016. PMID: 27240419 Free PMC article.
37 results